Former Alacer CEO joins UrgentRx board

DENVER — UrgentRx, developer of fast-acting over-the-counter flavored powder medications, on Tuesday named Ron Fugate to the company’s board of directors.

Previously, Fugate served as president and CEO of Alacer, makers of Emergen-C. Fugate and the Alacer team tripled the size of the Emergen-C business and led a highly competitive sale process that resulted in the sale of the company to Pfizer. Most recently, Fugate was president of YoCrunch (a Catterton Partners portfolio company), driving growth and innovation in the highly competitive yogurt and refrigerated dairy category, culminating with the sale of YoCrunch to Danone.

During his professional career, Fugate also held roles in sales and marketing at blue-chip consumer products companies including Johnson & Johnson, Kellogg’s, and Bristol-Myers Squibb. He has also served on the executive committee and board of the Council for Responsible Nutrition and as a member of the board of the Orange County Business Council.

“There is significant relevance and a strong analog in what UrgentRx is doing within the OTC category with what Ron accomplished at previous companies, notably Emergen-C in the vitamin category,” stated Jordan Eisenberg, president UrgentRx. “His impressive track record of disrupting staid market segments and transforming traditionally boring commodity-driven products into exciting, relevant brands will be a tremendous asset to the UrgentRx team. We look forward to working with him as we continue to build the UrgentRx brand.”

“I like the fact that UrgentRx really understands the needs of today’s consumer and is not afraid to shake things up in the health and beauty universe. UrgentRx products address a significant untapped need and their marketing and strategic direction are right on target," Fugate said.